Compounds > ro 24-5098
Page last updated: 2024-11-07

ro 24-5098

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Ro 24-5098: structure given in first source; has anti-HIV activity [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID124453
CHEMBL ID421506
SCHEMBL ID9679986
MeSH IDM0186169

Synonyms (16)

Synonym
CHEMBL421506
iso-dda
isodda
127682-75-1
[(2r,4r)-4-(6-aminopurin-9-yl)tetrahydrofuran-2-yl]methanol
l-threo-pentitol, 2-(6-amino-9h-purin-9-yl)-1,4-anhydro-2,3-dideoxy-
ro 24-5098
[(2r,4r)-4-(6-aminopurin-9-yl)oxolan-2-yl]methanol
ro24-5098
ro-24-5098
SCHEMBL9679986
(2r-cis)-4-(6-amino-9h-purin-9-yl)tetrahydro-2-furanmethanol
FJKGKWDFDNULCJ-RNFRBKRXSA-N
DTXSID40155624
((2r,4r)-4-(6-amino-9h-purin-9-yl)tetrahydrofuran-2-yl)methanol
AKOS040749330
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (11)

Assay IDTitleYearJournalArticle
AID31907In vitro effective dose which provides 50% protection of ATH-8 cells against the cytopathic effect of HIV; range 5-15 uM1992Journal of medicinal chemistry, Jun-26, Volume: 35, Issue:13
Synthesis and anti-HIV activity of isonucleosides.
AID32074The compound was tested for anti HIV-activity (active) against ATH8 cell line1999Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14
Correlation of anti-HIV activity with structure: use of electrostatic potential and conformational analysis.
AID232356Ratio of CC50 value that of EC50 value(HIV-2)1994Journal of medicinal chemistry, Oct-14, Volume: 37, Issue:21
Synthesis and evaluation of the anti-HIV activity of aza and deaza analogues of isoddA and their phosphates as prodrugs.
AID105158Effective concentration required to achieve 50% protection of MT-4 cells against cytopathic effect of HIV-1 (4 days)1994Journal of medicinal chemistry, Oct-14, Volume: 37, Issue:21
Synthesis and evaluation of the anti-HIV activity of aza and deaza analogues of isoddA and their phosphates as prodrugs.
AID82727Concentration required to inhibit HIV replication by 50%1992Journal of medicinal chemistry, Jun-26, Volume: 35, Issue:13
Synthesis and anti-HIV activity of isonucleosides.
AID82581The compound was tested for anti-HIV activity; Range = 5.0-15.0 uM1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
Synthesis and biological evaluation of 4-purinylpyrrolidine nucleosides.
AID106234The compound was tested for anti HIV-activity (active) against MT-4 cell line1999Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14
Correlation of anti-HIV activity with structure: use of electrostatic potential and conformational analysis.
AID104773Concentration required to reduce the viability of mock-infected MT-4 cells by 50% (4 days)1994Journal of medicinal chemistry, Oct-14, Volume: 37, Issue:21
Synthesis and evaluation of the anti-HIV activity of aza and deaza analogues of isoddA and their phosphates as prodrugs.
AID31902In vitro cytotoxicity against uninfected ATH-8 (human T-cell) cell line.1992Journal of medicinal chemistry, Jun-26, Volume: 35, Issue:13
Synthesis and anti-HIV activity of isonucleosides.
AID105159Effective concentration required to achieve 50% protection of MT-4 cells against cytopathic effect of HIV-2 (8 days)1994Journal of medicinal chemistry, Oct-14, Volume: 37, Issue:21
Synthesis and evaluation of the anti-HIV activity of aza and deaza analogues of isoddA and their phosphates as prodrugs.
AID232355Ratio of CC50 value that of EC50 value(HIV-1)1994Journal of medicinal chemistry, Oct-14, Volume: 37, Issue:21
Synthesis and evaluation of the anti-HIV activity of aza and deaza analogues of isoddA and their phosphates as prodrugs.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's7 (87.50)18.2507
2000's1 (12.50)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.25

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.25 (24.57)
Research Supply Index2.20 (2.92)
Research Growth Index4.45 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.25)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (12.50%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (87.50%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
dideoxyadenosine
Dideoxyadenosine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is an inhibitor of HIV replication, acting as a chain-terminator of viral DNA by binding to reverse transcriptase. Its principal side effect is nephrotoxicity. In vivo, dideoxyadenosine is rapidly metabolized to DIDANOSINE (ddI) by enzymatic deamination; ddI is then converted to dideoxyinosine monophosphate and ultimately to dideoxyadenosine triphosphate, the putative active metabolite.		4.3360adenosines;
purine 2',3'-dideoxyribonucleoside		EC 3.5.4.4 (adenosine deaminase) inhibitor;
EC 4.6.1.1 (adenylate cyclase) inhibitor
zidovudine
Zidovudine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia.. zidovudine : A pyrimidine 2',3'-dideoxyribonucleoside compound having a 3'-azido substituent and thymine as the nucleobase.		2.3920azide;
pyrimidine 2',3'-dideoxyribonucleoside		antimetabolite;
antiviral drug;
HIV-1 reverse transcriptase inhibitor
2,6-diaminopurine 2',3'-dideoxyriboside
2,6-diaminopurine 2',3'-dideoxyriboside: selectively inhibits HIV virus replication in vitro; structure given in first source		1.9810
2',3'-dideoxyadenosine triphosphate
[no description available]		1.9810purine deoxyribonucleoside triphosphate
oxetanocin a
oxetanocin: from Bacillus megaterium NK84-0218; structure given in first source. oxetanocin A : A nucleoside analogue found in Bacillus megaterium in which an adenine moiety is attached to position 2 of a of an oxetane ring which is substituted at positions 3 and 4 by hydroxymethyl groups.		210diol;
nucleoside analogue;
oxetanes;
primary alcohol		anti-HIV agent;
antibacterial agent;
bacterial metabolite
didanosine
Didanosine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. Didanosine is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA by binding to reverse transcriptase; ddI is then metabolized to dideoxyadenosine triphosphate, its putative active metabolite.. didanosine : A purine 2',3'-dideoxyribonucleoside that is inosine in which the hydroxy groups at both the 2' and the 3' positions on the sugar moiety have been replaced by hydrogen. An antiviral drug, it is used as a medication to treat HIV/AIDS.		2.3820purine 2',3'-dideoxyribonucleosideantimetabolite;
antiviral drug;
EC 2.4.2.1 (purine-nucleoside phosphorylase) inhibitor;
geroprotector;
HIV-1 reverse transcriptase inhibitor
2',3'-dideoxyguanosine
[no description available]		1.9810
ConditionIndicatedRelationship StrengthStudiesTrials
Experimental Leukemia
[description not available]		01.9710
HIV
Human immunodeficiency virus. A non-taxonomic and historical term referring to any of two species, specifically HIV-1 and/or HIV-2. Prior to 1986, this was called human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). From 1986-1990, it was an official species called HIV. Since 1991, HIV was no longer considered an official species name; the two species were designated HIV-1 and HIV-2.		03.320